	US 11,702,700 B2
	Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
Yurong Xin, Tarrytown, NY (US); Jesper Gromada, Tarrytown, NY (US); Xiping Cheng, Tarrytown, NY (US); Frederick Dewey, Tarrytown, NY (US); Tanya Teslovich Dostal, Tarrytown, NY (US); Claudia Schurmann, Tarrytown, NY (US); Aris Baras, Tarrytown, NY (US); and Noura Abul-Husn, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Feb. 18, 2021, as Appl. No. 17/178,420.
Application 17/178,420 is a continuation of application No. 16/157,503, filed on Oct. 11, 2018, granted, now 10,961,583.
Claims priority of provisional application 62/570,985, filed on Oct. 11, 2017.
Prior Publication US 2021/0246508 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)]

27 Claims

1. A method for treating a subject having a non-alcoholic liver disease, the method comprising administering an inhibitor of hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) to the subject;

wherein the subject has been determined to have a first nucleic acid molecule encoding a patatin like phospholipase domain containing 3 (PNPLA3) protein comprising an I148M variation and a second nucleic acid molecule encoding a functional HSD17B13 protein having oxidoreductase activity;

wherein the non-alcoholic liver disease is nonalcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH); and

wherein the inhibitor of HSD17B13 is an inhibitory nucleic acid molecule.